Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunic, Inc.

0.8958
+0.06277.53%
Post-market: 0.8778-0.0180-2.01%19:29 EDT
Volume:786.32K
Turnover:687.61K
Market Cap:85.83M
PE:-0.94
High:0.9199
Open:0.8400
Low:0.8357
Close:0.8331
Loading ...

Immunic Inc. Announces New Stock Appreciation Rights Plan for Employees and Executives, Pending Shareholder Approval

Reuters
·
12 Jul

Immunic Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Rule

Reuters
·
28 Jun

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
25 Jun

BRIEF-Immunic Reports New, Positive Long-Term Open-Label Extension Data

Reuters
·
24 Jun

Immunic Inc. Announces Positive Long-Term Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Reuters
·
24 Jun

Immunic Inc - Trial Achieved Primary and Secondary Endpoints With High Significance

THOMSON REUTERS
·
24 Jun

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 Emphasis Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

THOMSON REUTERS
·
24 Jun

Major Investment Alert: Insider Buys Thousands of Immunic Shares!

TIPRANKS
·
17 Jun

Duane Nash, Executive Chairman, Reports Acquisition of Common Shares in Immunic Inc

Reuters
·
17 Jun

Immunic Inc. President and COO Jason Tardio Reports Acquisition of Common Shares

Reuters
·
10 Jun

Immunic Inc. CEO and Director Daniel Vitt Reports Acquisition of Common Shares

Reuters
·
07 Jun

Director Makes Bold Move with Massive Immunic Stock Purchase

TIPRANKS
·
06 Jun

Director Joerg Neermann Reports Acquisition of Common Shares of Immunic Inc

Reuters
·
06 Jun

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
05 Jun

Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS

Reuters
·
05 Jun

Eqs-News: Immunic Announces Completion of Enrollment for Both Phase 3 Ensure Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 Calliper Trial in Progressive MS

THOMSON REUTERS
·
05 Jun

Immunic Inc - Top-Line Data for Phase 3 Ensure Trials Expected End of 2026

THOMSON REUTERS
·
05 Jun

Immunic (IMUX) Gets a Buy from Leerink Partners

TIPRANKS
·
05 Jun

Immunic Inc. Conducted Annual Stockholders Meeting

Reuters
·
05 Jun

Director Richard Alan Rudick Reports Acquisition of Immunic Inc. Common Shares

Reuters
·
05 Jun